1. Home
  2. ANIX

as 05-21-2024 12:36pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Founded: 1982 Country:
United States
United States
Employees: N/A City: SAN JOSE
Market Cap: 92.8M IPO Year: 1987
Target Price: $12.00 AVG Volume (30 days): 109.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.34 EPS Growth: N/A
52 Week Low/High: $2.75 - $5.13 Next Earning Date: 06-12-2024
Revenue: $210,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Anixa Biosciences Inc. (ANIX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Titterton Lewis H jr ANIX Director Apr 9 '24 Buy $3.28 15,009 $49,229.52 838,037 SEC Form 4
Baskies Arnold M ANIX Director Mar 15 '24 Buy $3.63 10,000 $36,300.00 110,000 SEC Form 4
KUMAR AMIT ANIX Chief Executive Officer Mar 15 '24 Buy $3.22 30,000 $96,600.00 491,925 SEC Form 4